Neuraly
Cambridge, United States· Est. 2016
Neuraly was founded to develop new drugs that change our expectations about successful treatment of progressive diseases like Alzheimer’s and Parkinson’s. We are developing drugs that address new pathways, capitalize on our founder’s innovation, and deliver medicines with the potential to change lives.
Private Company
Total funding raised: $71M
About
Neuraly was founded to develop new drugs that change our expectations about successful treatment of progressive diseases like Alzheimer’s and Parkinson’s. We are developing drugs that address new pathways, capitalize on our founder’s innovation, and deliver medicines with the potential to change lives.
Small Molecules
Funding History
2Total raised:$71M
Series B$53MJun 15, 2021
Series A$18MJun 15, 2018